Abstract
Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have